严重哮喘尿液代谢型显示肉碱代谢降低且独立于口服糖皮质激素治疗:U-BIOPRED研究
该研究在U-BIOPRED队列中前瞻性收集健康对照(n=100)、轻中度哮喘(n=87)和严重哮喘(n=418)的基线尿液,并对严重哮喘患者(n=305)进行12-18个月纵向采样,采用高分辨率质谱代谢组学分析。结果发现严重哮喘存在独立于口服糖皮质激素(OCS)的肉碱水平降低,且与线粒体功能障碍相关。
要点
- 严重哮喘尿液代谢型与健康及轻中度哮喘显著不同,且随时间稳定。
- 肉碱水平在严重哮喘中独立于OCS治疗而降低,为潜在治疗靶点。
- 肉碱降低与脂肪酸代谢通路富集评分下降及SLC22A5表达减少相关。
核心结论
- 严重哮喘患者尿液代谢型存在独立于OCS治疗的肉碱代谢降低,提示线粒体功能障碍在严重哮喘中的作用。
研究设计与样本
- 横断面U-BIOPRED队列研究,基线尿液来自健康参与者(n=100)、轻中度哮喘(n=87)和严重哮喘(n=418),纵向样本来自严重哮喘(n=305)。
- 采用高分辨率质谱获取代谢组学数据,并用单变量和多变量方法分析。
主要发现
- 共鉴定90种代谢物,其中40种在严重哮喘中显著改变(p<0.05,FDR<0.05),23种与OCS使用相关。
- 多变量建模显示健康参与者与轻中度哮喘患者的代谢型显著不同于严重哮喘(p=2.6×10-20),OCS治疗与未治疗哮喘患者间显著不同(p=9.5×10-4),纵向代谢型显示时间稳定性。
- 肉碱水平在严重哮喘中呈现最强的OCS非依赖性降低,且与脂肪酸代谢通路富集评分下降及痰和支气管刷检中肉碱转运体SLC22A5表达减少相关。
临床怎么用
- 严重哮喘的代谢评估需考虑OCS治疗影响,肉碱代谢可能作为独立于OCS的干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Asthma is a heterogeneous disease with poorly defined phenotypes. Patients with severe asthma often receive multiple treatments including oral corticosteroids (OCS). Treatment may modify the observed metabotype, rendering it challenging to investigate underlying disease mechanisms. Here, we aimed to identify dysregulated metabolic processes in relation to asthma severity and medication. METHODS: Baseline urine was collected prospectively from healthy participants (n=100), patients with mild-to-moderate asthma (n=87) and patients with severe asthma (n=418) in the cross-sectional U-BIOPRED cohort; 12-18-month longitudinal samples were collected from patients with severe asthma (n=305). Metabolomics data were acquired using high-resolution mass spectrometry and analysed using univariate and multivariate methods. RESULTS: A total of 90 metabolites were identified, with 40 significantly altered (p<0.05, false discovery rate <0.05) in severe asthma and 23 by OCS use. Multivariate modelling showed that observed metabotypes in healthy participants and patients with mild-to-moderate asthma differed significantly from those in patients with severe asthma (p=2.6×10-20), OCS-treated asthmatic patients differed significantly from non-treated patients (p=9.5×10-4), and longitudinal metabotypes demonstrated temporal stability. Carnitine levels evidenced the strongest OCS-independent decrease in severe asthma. Reduced carnitine levels were associated with mitochondrial dysfunction via decreases in pathway enrichment scores of fatty acid metabolism and reduced expression of the carnitine transporter SLC22A5 in sputum and bronchial brushings. CONCLUSIONS: This is the first large-scale study to delineate disease- and OCS-associated metabolic differences in asthma. The widespread associations with different therapies upon the observed metabotypes demonstrate the need to evaluate potential modulating effects on a treatment- and metabolite-specific basis. Altered carnitine metabolism is a potentially actionable therapeutic target that is independent of OCS treatment, highlighting the role of mitochondrial dysfunction in severe asthma.
引用
- Reinke SN, Naz S, Chaleckis R, et al. Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. Eur Respir J. 2022. PMID: 34824054. doi:10.1183/13993003.01733-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。